

Suguru Kadomoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9162055/publications.pdf>

Version: 2024-02-01

20
papers

619
citations

840119

11
h-index

839053

18
g-index

20
all docs

20
docs citations

20
times ranked

725
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic. <i>Cancer Science</i> , 2023, 114, 201-210.	1.7	4
2	Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 37, 102628.	1.3	4
3	Macrophage Polarity and Disease Control. <i>International Journal of Molecular Sciences</i> , 2022, 23, 144.	1.8	80
4	Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 72-80.	1.2	15
5	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. <i>Scientific Reports</i> , 2021, 11, 675.	1.6	16
6	Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?. <i>Journal of Robotic Surgery</i> , 2021, , 1.	1.0	0
7	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8530.	1.8	50
8	Three-dimensional morphological analysis of spermatogenesis in aged mouse testes. <i>Scientific Reports</i> , 2021, 11, 23007.	1.6	5
9	Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis. <i>Cancers</i> , 2020, 12, 89.	1.7	33
10	The CCL20-CCR6 Axis in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5186.	1.8	124
11	Reply to Comment on "Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis" <i>Cancers</i> 2020 12, 89. <i>Cancers</i> , 2020, 12, 354.	1.7	2
12	Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review. <i>World Journal of Men's Health</i> , 2020, 38, 132.	1.7	4
13	CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. <i>Cancer Science</i> , 2019, 110, 279-288.	1.7	40
14	C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. <i>Cancer Science</i> , 2018, 109, 724-731.	1.7	29
15	Tumor necrosis factor- α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. <i>Cancer Science</i> , 2018, 109, 1524-1531.	1.7	72
16	Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer. <i>Internal Medicine</i> , 2018, 57, 3123-3128.	0.3	9
17	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. <i>Oncotarget</i> , 2018, 9, 16185-16196.	0.8	26
18	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. <i>Anticancer Research</i> , 2018, 38, 2045-2055.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. <i>Oncotarget</i> , 2017, 8, 9739-9751.	0.8	98
20	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	3